TGFB1 and Hyperglycemia: Treatment with the PKC-δ inhibitor rottlerin, but not the cPKC inhibitor Gö6976, abrogated ERK expression and decreased hyperglycemia-induced responsiveness to TGF-β1 in mesangial cells, blocking the fibrotic response (71).